Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/19/2003US6608099 Indole sPLA2 inhibitors
08/19/2003US6608097 Materials and methods for the treatment of hypertension and angina
08/19/2003US6608089 Derivatives of flavones, xanthones and coumarins
08/19/2003US6608087 Gyrase inhibitors and uses thereof
08/19/2003US6608084 Treatment of human or non-human animal patient suffering from, or subject to, condition which can be ameliorated by administration of inhibitor of alpha 4 beta 1 mediated cell adhesion
08/19/2003US6608083 Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease,
08/19/2003US6608077 Il-8 receptor antagonists
08/19/2003US6608076 Treating topoisomerase I inhibitor-related disease in mammals
08/19/2003US6608071 Angiogenesis inhibitors as antitumor agents
08/19/2003US6608070 Useful for treatment of medical condition in which prostaglandins are implicated as pathogens
08/19/2003US6608069 Phenyl xanthine derivatives
08/19/2003US6608068 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
08/19/2003US6608067 Inhibitors of serine proteases, particularly HCV NS3 protease
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6608057 Compounds useful as reversible inhibitors of cathepsin S
08/19/2003US6608046 β-lactamase and DD-peptidase inhibitors
08/19/2003US6608044 Inhibition of TNF activity
08/19/2003US6608043 Administering complex of hyaluronic acid and zinc to patient having arthritic disease
08/19/2003US6608036 Oligonucleotide N3′→P5′ thiophosphoramidates: their synthesis and administration to treat neoplasms
08/19/2003US6608034 Immunovectors for the intracellular and intranuclear transport
08/19/2003US6608032 Medicinal compositions
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
08/19/2003US6608029 Reducing gastric motility or delaying gastric emptying in mammal by administering therapeutically effective amount of amylin or amylin agonist, such as pramlintide or pramlintide acetate
08/19/2003US6607880 Methods and reagents for modulating apoptosis
08/19/2003US6607758 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
08/19/2003US6607749 Non-fermentable methyl cellulose, lipase inhibitor and edible calcium phosphate salt; fecal incontinence, obesity
08/19/2003US6607743 Milk-derived basic cystatins or decomposition products; foods, beverages, feeds
08/19/2003US6607742 Suppository composition which is a spray-dried suspension of an acid-labile proton pump inhibitor in a solvent solution of a sterol and polymer
08/19/2003US6607741 Conjugates of sodium channel blockers and methods of using the same
08/19/2003US6607726 Human tumor necrosis factor receptor TR10
08/19/2003US6607724 Administering fragments, conformations, biological equivalent, or derivatives of antithrombin III; anticancer agents
08/19/2003US6607722 Methods for inducing the differentiation of monocytes into functional dendritic cells
08/19/2003US6607501 Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
08/19/2003CA2433180A1 Apoptosis promoting and suppressing substances interacting with cgi-94, and methods for screening the same
08/19/2003CA2299972C Thyromimetic antiobesity agents
08/19/2003CA2260337C Therapeutic agents
08/19/2003CA2138258C Synthetic peptides for the treatment of myasthenia gravis
08/19/2003CA2099867C 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
08/19/2003CA2099061C Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
08/19/2003CA2079376C (bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
08/19/2003CA2079375C (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
08/19/2003CA2070254C Thrombin inhibitors
08/19/2003CA2066532C Pharmaceutical compositions
08/19/2003CA2012414C Hog cholera virus vaccine and diagnostic
08/14/2003WO2003067262A2 Methods and compositions involving the hsp90 activator aha1
08/14/2003WO2003066889A2 Assay for acytyltransferase or deacetylase activity
08/14/2003WO2003066860A1 Angiogenesis inhibitors
08/14/2003WO2003066854A1 Anticancer agents using vero toxin variants
08/14/2003WO2003066840A2 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
08/14/2003WO2003066822A2 Truncated aggrecanase molecules
08/14/2003WO2003066807A2 Method of inhibiting pathogenicity of infectious agents
08/14/2003WO2003066672A1 Peptides
08/14/2003WO2003066671A1 Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof
08/14/2003WO2003066666A2 Compositions and methods for treatment of vitamin d deficiency
08/14/2003WO2003066661A2 Human dr4 antibodies and uses thereof
08/14/2003WO2003066636A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/14/2003WO2003066635A1 Piperidine derivatives
08/14/2003WO2003066634A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
08/14/2003WO2003066630A2 Quinolinone derivatives for treating cell proliferation related disorders
08/14/2003WO2003066621A1 Piperidine derivatives and their use as antagonists of tachykinins
08/14/2003WO2003066618A1 Cytoprotective benzofuran derivatives
08/14/2003WO2003066613A1 N-phenyl-2-pyrimidine-amine derivatives
08/14/2003WO2003066608A1 Catechol bioisosteres
08/14/2003WO2003066606A1 Salts of valsartan
08/14/2003WO2003066604A2 Novel aryl- and heteroarylpiperazines
08/14/2003WO2003066601A1 Pyrimidine compounds
08/14/2003WO2003066596A1 Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b)
08/14/2003WO2003066595A2 2 - piperazine - pyridines useful for treating pain
08/14/2003WO2003066593A2 Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
08/14/2003WO2003066592A1 Gamma secretase inhibitors
08/14/2003WO2003066591A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
08/14/2003WO2003066590A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
08/14/2003WO2003066589A1 Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
08/14/2003WO2003066581A1 Urea linker derivatives for use as ppar modulators
08/14/2003WO2003066579A2 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
08/14/2003WO2003066574A1 Aromatic amino acid derivatives and medicinal compositions
08/14/2003WO2003066205A2 Microcapsules having high carotenoid content
08/14/2003WO2003066165A1 Tumor necrosis factor combined with interferon in demyelinating diseases
08/14/2003WO2003066104A2 Pharmaceutical composition which improves in vivo gene transfer
08/14/2003WO2003066100A1 Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
08/14/2003WO2003066099A1 2,4,6-triamino-1,3,5-triazine derivative
08/14/2003WO2003066097A2 A novel target to inhibit angiogenesis
08/14/2003WO2003066091A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
08/14/2003WO2003066089A1 Megsin ligands
08/14/2003WO2003066087A2 Kinases involved in the regulation of energy homeostasis
08/14/2003WO2003066080A1 Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans
08/14/2003WO2003066076A1 Method of protecting living body from foreign factor and composition therefor
08/14/2003WO2003066063A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
08/14/2003WO2003066061A1 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
08/14/2003WO2003066059A1 Treatment of neuroblastoma
08/14/2003WO2003066056A1 Method of promoting neuronal growth
08/14/2003WO2003066055A1 Quinoline derivatives as npy antagonists
08/14/2003WO2003066050A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003WO2003066047A1 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
08/14/2003WO2003066045A1 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan
08/14/2003WO2003066043A1 Stimulation of cpt-1 as a means to reduce weight
08/14/2003WO2003066040A1 Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
08/14/2003WO2003066035A2 Compounds for inhibiting insulin secretion and methods related thereto
08/14/2003WO2003066030A2 Pharmaceutical tablet
08/14/2003WO2003066004A2 Therapeutic compounds
1 ... 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 ... 1564